Copyright
©The Author(s) 2018.
World J Clin Oncol. Jun 10, 2018; 9(3): 42-55
Published online Jun 10, 2018. doi: 10.5306/wjco.v9.i3.42
Published online Jun 10, 2018. doi: 10.5306/wjco.v9.i3.42
Figure 1 Ribonucleotide RNA modifications known to be of relevance in cancer and their enzymatic machineries.
m6A: N6-methyladenosine; METTL3: Methyltransferase like 3; METTL14: Methyltransferase like 14; WTAP: Wilms’ tumor 1-associating protein; m6A erasers (ALKBH5: Alkylation repair homologue protein 5; FTO: Fat mass and obesity-associated protein); Inosine (I) writers [ADAR1 (p110 and p150) and ADAR2: Adenosine deaminase acting on RNA 1 and 2]; 5-methylcytosine (5mC) (NSUN2: NOP2/Sun domain protein 2; TRDMT1: tRNA aspartic acid MTase 1); 2’O-methylation writers (Nol5a: Nucleolar Protein 5A; Nop58: Nucleolar protein 58; Snu13: Small Nuclear Ribonucleoprotein 13; SnoRNA: Small nucleolar RNA).
- Citation: Tusup M, Kundig T, Pascolo S. Epitranscriptomics of cancer. World J Clin Oncol 2018; 9(3): 42-55
- URL: https://www.wjgnet.com/2218-4333/full/v9/i3/42.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i3.42